Trade Report: Today, Genomic Health Inc. (GHDX) COO Sold $253,591.10 in Stock

Today, Genomic Health Inc. (GHDX) COO Sold $253,591.10 in Stock

Genomic Health Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 8,290 shares of the stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $30.59, for a total value of $253,591.10. Following the completion of the transaction, the chief operating officer now directly owns 39,426 shares of the company’s stock, valued at $1,206,041.34. The sale was disclosed in a filing with the SEC, which is available through this link.

G Bradley Cole also recently made the following trade(s): On Thursday, August 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $28.87, for a total value of $144,350.00.

Genomic Health Inc. (NASDAQ:GHDX) opened at 29.30 on Monday. Genomic Health Inc. has a 52 week low of $20.05 and a 52 week high of $35.79. The firm’s 50-day moving average price is $28.36 and its 200-day moving average price is $27.34. The company’s market capitalization is $977.04 million.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, hitting analysts’ consensus estimates of ($0.18). The firm earned $81.97 million during the quarter, compared to analysts’ expectations of $81.27 million. Genomic Health had a negative net margin of 8.84% and a negative return on equity of 21.02%. The company’s revenue for the quarter was up 16.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.29) earnings per share. On average, equities analysts expect that Genomic Health Inc. will post ($0.47) earnings per share for the current year.

A number of equities analysts recently issued reports on the company. Zacks Investment Research raised Genomic Health from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a report on Tuesday, October 4th. Jefferies Group increased their price objective on Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, August 17th. Canaccord Genuity reissued a “buy” rating and issued a $38.00 price objective on shares of Genomic Health in a report on Friday, August 5th. Bank of America Corp. set a $28.00 price objective on Genomic Health and gave the stock a “sell” rating in a report on Wednesday, August 3rd. Finally, Leerink Swann reissued a “buy” rating on shares of Genomic Health in a report on Tuesday, June 21st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $32.50.

Hedge funds and other institutional investors have recently made changes to their positions in the company. HBK Investments L P acquired a new position in shares of Genomic Health during the first quarter worth approximately $886,000. California State Teachers Retirement System boosted its position in shares of Genomic Health by 4.0% in the second quarter. California State Teachers Retirement System now owns 39,167 shares of the company’s stock worth $1,014,000 after buying an additional 1,510 shares in the last quarter. Kimelman & Baird LLC boosted its position in shares of Genomic Health by 2.3% in the first quarter. Kimelman & Baird LLC now owns 21,940 shares of the company’s stock worth $543,000 after buying an additional 500 shares in the last quarter. Loomis Sayles & Co. L P acquired a new position in shares of Genomic Health during the first quarter worth approximately $15,639,000. Finally, Royce & Associates LP boosted its position in shares of Genomic Health by 15.7% in the second quarter. Royce & Associates LP now owns 88,500 shares of the company’s stock worth $2,292,000 after buying an additional 12,000 shares in the last quarter. Hedge funds and other institutional investors own 88.92% of the company’s stock.

About Genomic Health

Related posts

Leave a Comment